Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402590 | 0.82 | KMT2A (0.49) | PDE4BKMT2AL3MBTL1CTSLSYK | |
| SCHEMBL19635978 | 0.82 | SMN1; SMN2 (0.45) | KMT2ACTSLHTTSMN1; SMN2NPC1 | |
| SCHEMBL17157135 | 0.81 | SMN1; SMN2 (0.53) | PDE4BKMT2AL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL20836080 | 0.80 | GAA (0.38) | KMT2AL3MBTL1CTSKGAA | |
| SCHEMBL15669949 | 0.79 | USP30 (0.53) | PDE4BKMT2AL3MBTL1CTSLHTT | |
| SCHEMBL15669841 | 0.79 | PDK1 (0.47) | PDE4BKMT2AL3MBTL1CTSLSYK | |
| SCHEMBL26602429 | 0.79 | USP30 (0.53) | PDE4BKMT2AL3MBTL1CTSLHTT | |
| SCHEMBL304546 | 0.78 | SMN1; SMN2 (0.58) | PDE4BKMT2AL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL19635976 | 0.77 | SMN1; SMN2 (0.48) | KMT2AL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29675175 | 0.75 | KMT2A (0.45) | PDE4BKMT2AL3MBTL1CTSLSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708165-B1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | SINOMAB BIOSCIENCE LTD (CN) | 2023-01-18 | — | — | EP | disclosed |
| EP-3459940-B1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | SUZHOU SINOVENT PHARMACEUTICALS CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11180475-B2 | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor | SINOMAB BIOSCIENCE LIMITED (HK) | 2021-11-23 | — | — | US | disclosed |
| US-10882843-B2 | 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-01-05 | — | — | US | disclosed |
| US-20200361902-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | SUZHOU SINOVENT PHARMA CO., LTD. (CN) | 2020-11-19 | — | — | US | disclosed |
| EP-3708165-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | Sinomab Bioscience Limited (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20190152952-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3459940-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Zhejiang Yukon Pharma Co., Ltd. (CN) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198050-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | 浙江予川医药科技有限公司 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882843-B2 | 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof | BTK, SYK, LCK | PDE4B 325/4885KMT2A 918/4885L3MBTL1 4681/4885 |
| US-20200361902-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | BTK, SYK, LCK | PDE4B 820/4885KMT2A 1130/4885L3MBTL1 3943/4885 |
| US-11180475-B2 | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor | BTK, SYK, LCK | PDE4B 820/4885KMT2A 1130/4885L3MBTL1 3943/4885 |
| US-20190152952-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | BTK, SYK, LCK | PDE4B 325/4885KMT2A 918/4885L3MBTL1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.